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Cough variant asthma (CVA), a common asthma phenotype characterized by nonproductive
cough and bronchial hyperreactivity (BHR), is usually detected by bronchial provocation tests
(BPTs) which are time-consuming, expensive, and unsafe. The primary study objective was to
provide proof of concept for the use of fractional exhaled nitric oxide (FENO), eosinophil count
percentage in induced sputum (sEOS%), forced expiratory flow between 25 and 75% of
forced vital capacity (FEF25–75%) % predicted value, and FEF25–75% z-scores as surrogate
markers predicting BHR in young adults with suspected CVA; the secondary objective was to
compare the diagnostic performance of the various techniques. Three hundred and ten
subjects (median age 24 years) were included in a cross-sectional study. Subjects were
characterized as BHR positive (POS) (n  147) or BHR negative (NEG) (n  163) according to
methacholine BPT. Classification accuracies were expressed as areas under the receiver
operator characteristic curves (AUC). Compared with BHR NEG, FEF25–75% % predicted
value and FEF25–75% z-scores were lower in the BHR POS group (p < 0.001), whereas FENO
(p < 0.001) and sEOS% were higher (p < 0.001). AUC values for detecting BHR were
as follows: FENO, 0.98 (SD  0.02); sEOS%, 0.98 (SD  0.02); FEF25–75% % pred, 0.93
(SD  0.05); FEF25–75% z scores, 0.92 (SD  0.05). Optimal cutoff values (OCV) for BHR
prediction were as follows: FENO, 32.7 ppb (sensitivity  0.93, specificity  0.96), sEOS
%, 3.80% (sensitivity  0.94, specificity  0.94), FEF25–75% % predicted value, 80.0%
(sensitivity  0.90, specificity  0.87), and FEF25–75% z-score, −0.87 (sensitivity  0.89,
specificity  0.87). Non-invasive/semi-invasive airway inflammatory or small airway
functional measures might be used as surrogate markers predicting BHR in young
adults with suspected CVA.
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INTRODUCTION
Asthma is characterized by chronic airway inflammation,
bronchial hyperreactivity (BHR), and episodes of
bronchoconstriction clinically presenting as variable and
recurring cough, dyspnea, and wheezing (ginasthma, 2020).
Asthma is a heterogeneous disease, including a broad spectrum
of diseases described as various phenotypes (Haldar et al., 2008).
Cough variant asthma (CVA), a frequent asthma phenotype, is
characterized by a cough as a prevalent symptom andBHR (Corrao
et al., 1979). The presence of BHR is generally detected with
bronchial provocation tests (BPTs), a positive response to
bronchodilators or both (Irwin et al., 2006; Achilleos, 2016).
BPTs are the gold standard, but expensive, time consuming,
and unsafe as they are potentially able to induce severe
bronchospasm (Coates et al., 2017). Simpler, safer, and more
rapid predictive methods would be relevant to clinical practice
(Bao et al., 2018) as they would facilitate the identification of those
patients with suspected CVA who need to be referred for BHT.
Fractional exhaled nitric oxide (FENO) is a non-invasive,
standardized, safe, simple, and well-accepted surrogate marker of
airway inflammation (Jatakanon et al., 1998b; ElHalawani et al., 2003;
Berkman et al., 2005; Malerba et al., 2008). FENO is elevated in
subjects with atopic asthma (Ricciardolo et al., 2004) and correlates
with sputum eosinophilia before and after glucocorticoid treatment
(Jatakanon et al., 1998b; Malerba et al., 2008), and with
bronchoalveolar lavage (BAL) eosinophil counts (Lim et al., 1999);
a strong correlation between FENOconcentrations andBHRhas been
observed in children with asthma (Ciprandi et al., 2010). FENO levels
were also found correlated with BHR in apprentices exposed to
occupational risk for asthma (Tossa et al., 2010).
Increasing evidence shows that inflammation of small airways
(<2 mm diameter) and surrounding alveolar tissue and small
airway function play a pivotal pathophysiological role in cough
exacerbation, nocturnal attacks, and exercise-induced wheeze (Van
Der Wiel et al., 2013). Forced expiratory flow between 25 and 75%
of forced vital capacity (FEF25–75%) has been found to correlate
with functional imaging assessment of small airway function (Jain
et al., 2005) and proposed as an early marker for peripheral airway
airflow limitation (<2 mm) (McFadden and Linden, 1972; Terra
Filho et al., 1986; Perez et al., 2013) and eosinophilic inflammation
(Malerba et al., 2016). Using computed tomography airway
morphometric analysis, (Niimi et al., 2000), several studies have
shown a good correlation between FEF25–75% and the High-
Resolution computed tomography finding of air trapping.
Recently, FEF25–75% has been shown to be feasible parameter
for identifying small airway dysfunction early in CVA patients
(Yuan et al., 2019). Moreover, in a cross sectional study, reduced
FEF25–75% was associated with increased frequency of respiratory
symptoms, greater healthcare utilization and higher levels of
biomarkers of distal airway inflammation, including FENO and
sputum eosinophils (Riley et al., 2015).
Eosinophil differential count in induced sputum (sEOS%), a
semi-invasive technique, is a standardized, recommended,
evidence-based, direct measure of airway inflammation and its
use is reported into the most relevant guidelines (Pin et al., 1992).
sEOS% counts increase during asthma exacerbations (Pizzichini
et al., 1999) and, similarly to FENO concentrations, decrease after
treatment with corticosteroids (Jatakanon et al., 1998a). The
primary objective of this study was to provide proof of
concept for the use of various noninvasive/semi-invasive
inflammatory or functional measures, including FENO, sEOS%
and FEF25–75%, as surrogate markers predicting BHR in a cohort
of young adults with suspected CVA and maintained lung
function as reflected by normal forced expiratory volume in
1 s percentage of predicted (FEV1%) values; secondary study
objective was to compare their diagnostic performance. We
chose to study subjects aged from 18 to 45 years to minimize
the impact of confounding factors related to airways aging and
possible co-morbidities associated with older ages on study
outcomes.
METHODS
Subjects and Study Design
We performed a cross-sectional study of data collected from 310
adult subjects aged from 18 to 45 years referred for cough to the
Respiratory Medicine Unit of the Department of Internal
Medicine, University of Brescia and to the Department of
Translational Medicine, University of Piemonte Orientale,
Respiratory Unit of Vercelli’s Hospital, Italy, in an out-subject
setting from January 2016 to March 2018.
Inclusion criteria were as follow: suspected CVAwith cough as a
predominant symptom, chest tightness, dyspnea or wheezing with
nocturnal awakenings for >3 weeks; normal chest X-ray;
maintained lung function as reflected by FEV1% > 80% of
predicted values with spirometric measurement. Subjects were
excluded if they met the following criteria: upper respiratory
infection during the previous 6 weeks, use of systemic and/or
inhaled corticosteroids during the previous 6 weeks, current or past
history of smoking, any significant medical condition, a
prior asthma diagnosis and the usual contraindications to
methacholine challenge tests. No subject was under
antihistamines and no subject had symptoms of allergic rhinitis
at the time of the inclusion. The study was approved by the Local
Center Ethics Committees (N 0770-2016 and N 035 -2017) and all
the subjects gave their written informed consent. Recruited subjects
underwent the following procedures: clinical examination;
symptom evaluation; skin prick testing; pulmonary function
tests; methacholine challenge test; FENO measurement; sputum
induction, and sEOS% count. Interventions were performed in the
following order to reduce the effect of bronchoconstriction on
FENO: FENO measurement, spirometry, methacholine challenge
and sputum induction (American Thoracic Society, European
Respiratory Society, 2005).
This study was conducted in agreement with the STROBE
statement for observational studies (von Elm et al., 2008).
Skin Prick Test
Allergy was assessed by skin prick test positivity to the most
common respiratory allergens as stated by the European
Academy of Allergy and Clinical Immunology (Anonymous,
1989).
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Pulmonary Function Tests
Pulmonary function measures were obtained using a
pneumotachograph with a volume integrator (CAD/Net system
1070; Medical Graphics Corporation, St. Paul, Minn., United
statesSA), following American Thoracic Society criteria (Clausen
et al., 1997). Spirometric parameters were expressed as percent of
predicted values and z-scores. Predicted values and z-scores were
derived using prediction equations from the Global Lung Function
Initiative (GLI-2012; http://www.lungfunction.org/) (Quanjer et al.
, 1993; Quanjer et al., 2012). Only pre-bronchodilator data were
included in the study data analysis.
Bronchial Provocation Test
A methacholine challenge test was performed as a dose-response
curve by increasing (doubling) doses of methacholine
chlorohydrate every 3 min according to international
guidelines (Pizzichini et al., 1999). Results were expressed as
cumulative doses of methacholine provoking a 20% fall in FEV1
(PD20 FEV1). Amethacholine challenge test result was considered
positive if the PD20 FEV1 was <16.00 mg/ml (Crapo et al., 2000).
FENO
FENOwas determined with a high-resolution chemiluminescence
NO analyser (Ecomedics AG Analyzer CLD88; Dur̈nten,
Switzerland), with detection limit of 0.06 ppb and
measurement range reaching 100 ppb. FENO was measured at
a flow rate of 50 ml/s as per ATS/ERS guidelines. Measurements
were obtained in accordance with the ATS recommendations for
on-line measurement of FENO in adults (American Thoracic
Society, European Respiratory Society, 2005).
Sputum Induction
After baseline FEV1 and FVC measurements, subjects were pre-
treated with inhaled salbutamol (200 μg by metered-dose inhaler)
and 10 min later were asked to inhale a hypertonic (4.5%)
nebulized sterile saline solution for three periods of 5 min each
at most by means of an ultrasonic nebulizer (Ultraneb 2000;
DeVilbiss, Somerset, PA, USA). Nebulization was discontinued if
one of the following symptoms occurred: wheezing, chest
tightness or moderate-to-severe dyspnea. Sputum was
processed as previously reported (Malerba et al., 2006). The
cut-off for an abnormal result was considered a sEOS% value
> 3% of total non-squamous cells (Balbi et al., 2007).
Statistical Analysis
In an opportunistic sample of 310 young adults with CVA, we
aimed to provide a proof of concept for the use of FENO, sEOS%,
FEF25–75% predicted value, and FEF25–75% z scores as surrogate
markers predicting BHR. Subject characteristics have been
summarized according to BHR status. The normality Shapiro
Wilk test was performed for assessing data distribution. Normally
distributed data were expressed as mean and the standard
deviation (SD); nonparametric data were expressed as median
and interquartile range (25th to 75th percentiles); categorical data
were expressed as percentage and absolute numbers. Wilcoxon
rank sum test or t-test, depending on data distribution, was
performed for continuous data between-group comparisons;
Pearson chi-square test or Fisher-exact test, whatever
appropriate, was used for categorical variable between-group
comparisons. Correlations between PD20 FEV1, sEOS% and
FENO were expressed as Spearman Rho correlation coefficient.
FEF25–75% was also expressed as a z-score using the regression
equation and variance derived from a normal population assessed
in our laboratory. FEF25–75% z-score was calculated as the
difference between the measured and predicted FEF25–75%
value divided by the reference SD (Jones et al., 2003). A Z
score that equaled zero indicated the subject’s pulmonary
function was at the predicted value, whereas Z scores of 1 and
−1 indicated pulmonary function that was 1 SD above and below
the predicted values, respectively.
The predictive accuracies for each BHR predictor have been
estimated via logistic regression models. The estimates have been
adjusted by gender and age and validated performing a 10 fold
repeated cross-validation procedure. Receiver operating
characteristic (ROC) curves, sensitivity and specificity values
with relative standard deviations computed across iterations
have been reported. ROC curves for the leading predictors
have also been reported.
Optimal cut off values (OCV) for BHR prediction were
estimated as the values combining the best sensitivity and
specificity for BHR POS detection. The Youden index (J), a
main summary statistic of the ROC curve, was used
as a measure of model quality (Youden, 1950). Statistical
analysis has been performed using R 3.2.5 (R Core Team.,
2018), together with caret (Kuhn, 2008) and pROC packages
(Robin et al., 2011).
RESULTS
Baseline Characteristics of Subjects
Studied
Clinical data from 310 subjects were included in the analysis.
Subjects were divided in two groups based on methacholine BPT
results. Subjects with positive BPT were categorized as BHR POS
(n  147); if BPT was negative, subjects were identified as BHR
NEG (n  163).
There was no between-group difference in age (p  0.36) and
gender (p  0.73), whereas allergy was more prevalent in BHR
POS (68%) than in BHR NEG (6%) (p < 0.001) (Table 1). One
hundred ten subjects (35%) were sensitized to perennial and/or
pollen allergens. Subjects were all ex smokers or non-smokers.
Functional and Inflammatory Biomarkers
In all subjects, FVC, FEV1 and FEV1/FVC values were within
normal reference ranges showing no significant differences
between BHR POS and BHR NEG group (Table 1).
By contrast, median FEF25–75% z-score (p < 0.001) and
FEF25–75% % predicted value (p < 0.001) were both
significantly lower in the BHR POS than BHR NEG group
(Table 1), suggesting that small airways disease was present in
the former.
FENO (p < 0.001) and sEOS% median values (p < 0.001) were
elevated in the BHR POS group compared with BHR NEG group
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(Table 1). Mean PD20 FEV1 was 642 ± 489 μg. FENO
concentrations were correlated with PD20 FEV1 values (rho 
−0.88; p < 0.001). FENO and sEOS% values were highly correlated
(rho  0.886 p < 0.001).
Diagnostic Accuracy of Single
Measurements for BHR Prediction
Logistic regression analysis showed that measurement of FENO,
sEOS%, FEF25–75% z-score, and FEF25–75% % predicted values
were able to predict BHR with high accuracy, sensitivity and
specificity (Table 2). FENO and sEOS% were the best performing
techniques as reflected by their AUC values (0.98 for both)
(Figure 1), and sensitivity and specificity values, which were
above 0.92 (Table 2). AUCs for FEF25–75% % pred and FEF25–75%
z-score were >0.91, with sensitivity and specificity values > 0.86
(Figure 1; Table 2).
OCV for BHR prediction were as follows: FENO, 32.7 ppb
(sensitivity  0.93, specificity  0.96), sEOS%, 3.80% (sensitivity 
0.94, specificity 0.94), FEF25–75% % predicted, 80.0% (sensitivity
0.90, specificity  0.87), and FEF25–75% z-score, -0.87 (sensitivity 
0.89, specificity  0.87). Youden J values of various techniques for
predicting BHR are shown in Table 1.
DISCUSSION
Our study provided proof of concept that non-invasive/semi-
invasive measures reflecting airway inflammation or small-airway
function might be used as surrogate markers of BHR in young
adults with suspected CVA and normal lung function. Predictive
models were of high quality as reflected by values of Youden’s
index (J), the maximum potential effectiveness of a biomarker
which combines sensitivity and specificity (Youden, 1950),
ranging from 0.76 to 0.89. We confirmed the potential utility
of FENO and FEF25–75% predicted value measurement in
predicting the presence of BHR in subjects with suspected
CVA and extend this observation to eosinophil counts in
induced sputum. Of note, in our study, the discriminant
abilities of the various methods were remarkably higher than
those reported in previous studies (Schleich et al., 2012; Bao et al.,
2018; Chen et al., 2019), This discrepancy might reflect
TABLE 1 | Subject characteristics in positive and negative bronchial hyperreactivity (BHR) groups.
BHRneg BHRpos Combined p
Number 163 147 310
Female 64% (104) 62% (91) 63% (195) 0.73
Age, years 25.1 (31.1–35.8) 23.3 (29.4–35.2) 24.0 (30.0–35.7) 0.36
Allergy 6% (10) 68% (100) 35% (110) <0.001
ICS treatment, yes/no 0/163 0/147 0/310
History of smoking, yes/no 0/163 0/147 0/310
FEV1, % pred 97.8 (98.7–99.4) 98.0 (99.1–100.0) 97.9 (98.9–99.7) 0.064
FVC, % pred 98.3 (99.2–100.3) 98.4 (99.5–101.1) 98.3 (99.3–100.7) 0.059
FEV1/FVC, % 0.820 (0.830–0.840) 0.820 (0.830–0.850) 0.820 (0.830–0.850) 0.76
FEF25–75%, z-score −0.605 (0.37–0.76) −2.77 (−1.96–−1.14) −2.005 (−0.815–0.445) <0.001
FEF25–75%, % pred 86 (110–120) 44 (57–72) 56 (81–111) <0.001
FENO, ppb 17.8 (19.3–21.9) 42.5 (56.6–63.0) 19.0 (28.0–55.0) <0.001
sEOS, % 0.0 (0.0–1.4) 6.4 (7.9–11.7) 0.0 (2.6–7.6) <0.001
PD20 FEV1 1600/1600/1600 195/570/1000 605/1600/1600 <0.001
Continuous data are reported as median and interquartile range (25th to 75th percentiles); categorical data are reported as a percentage and numbers. Wilcoxon rank sum test was
performed for continuous variable comparisons and the Pearson chi-square test or Fisher-exact test, whatever appropriate, was used for categorical variable comparisons. Abbreviations:
BHR, bronchial hyperresponsiveness; ICS, inhaled corticosteroids; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; FEF25–75%, forced expiratory flow between 25 and
75% of FVC; FENO, fractional exhaled nitric oxide; pred: predicted value; sEOS%, percentage of eosinophil differential cell count in induced sputum.
TABLE 2 | BHR predictive accuracies of FENO measurement, percentage of sputum eosinophil cell counts, FEF25%–75% of predicted value, and FEF25%–75% z-score in 310
subjects with suspected cough variant asthma.a
AUC AUC SD Sens Sens SD Spec Spec SD Cut off PPV NPV Accuracy PLR NLR Youden
index
FENO 0.98 0.02 0.93 0.07 0.96 0.05 32.70 0.95 0.93 0.94 21.56 0.08 0.89
sEOS 0.98 0.02 0.94 0.07 0.94 0.05 3.80 0.94 0.95 0.94 17.01 0.06 0.88
FEF25–75% % pred 0.93 0.05 0.90 0.07 0.87 0.07 80.00 0.86 0.91 0.89 6.96 0.11 0.77
FEF25–75% z-score 0.92 0.05 0.89 0.09 0.87 0.09 −0.87 0.86 0.90 0.88 6.71 0.12 0.76
aArea under the receiver operator characteristic (ROC) curve (AUC), sensitivity, specificity, with standard deviations (SD), optimal cut-points (cutoff), negative and positive predictive values,
and likelihood ratios are shown. The predictive accuracies have been estimated via logistic regression models adjusted by gender and age, performing a 10 fold repeated (10 times) cross-
validation procedure. Abbreviations: AUC, area under receiver operator characteristic (ROC) curve; SD, standard deviation; Sens, sensitivity; spec, specificity; PPV, positive predictive
value; NPV, negative predictive value; PLR, positive likelihood ratio; NRL, negative likelihood ratio; FENO: fractional exhaled nitric oxide; sEOS, eosinophil count in induced sputum;
FEF25%-75%, forced expiratory flow between 25 and 75% of forced vital capacity; pred, predicted.
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differences in study population characteristics, including age,
ethnicity, and lung function, across various studies.
We observed that young adults with suspected CVA and
normal lung function having FENO >37.2 ppb, sEOS% >3.8%,
FEF25–75% % pred <80% and zFEF25–75% <-0.87% have elevated
probability of being BHR POS and classification accuracy >91%
(98% for both FENO and sEOS%). These findings support a close
relationship between airway inflammation and peripheral airway
function.
FENO is a surrogate marker of airway inflammation,
particularly useful in patients with atopic eosinophilic asthma
(Berkman et al., 2005; Gibson, 2009; Dweik et al., 2011). FeNO
was proposed to be able also to predict ICS responsiveness in
chronic cough although supported by few studies and without a
strong evidence (Song et al., 2017b).
In individuals with chronic cough (Maniscalco et al., 2015;
Chen et al., 2019), FENO is able to distinguish CVA and
eosinophilis bronchitis from other causes of chronic cough. A
FIGURE 1 | ROC curves of (A) FENO (B) sEOS% (C) FEF25–75%%pred (D) zFEF25–75% in predicting positive BHR. ROC, receiver operating characteristic; FENO,
fractional exhaled nitric oxide; sEOS%, percentage of eosinophils in induced sputum; FEF25–75%, forced expiratory flow at 25–75% of forced vital capacity: AUC, Area
under the curve; SD standard deviation.
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recent meta-analysis pointed out that Fractional exhaled nitric
oxide (FeNO) has moderate diagnostic accuracy for predicting
cough variant asthma (CVA) with high specificity in patients with
chronic cough (Song et al., 2017a). We observed a strong
correlation between FENO and sEOS% values consistent with
previous reports on the ability of FENO to reflect eosinophilic
airway inflammation (Cirillo et al., 2013; Ricciardolo, 2014).
In the present study, FENO showed a remarkable predictive
ability to detect BHR (AUC: 0.98; sensitivity: 0.93; specificity:
0.96; PPV: 0.95; NPV: 0.93) at a cutoff value of >32.7 ppb, higher
than that reported in previous studies at FENO cutoff values
of 43 ppb (AUC: 0.79; sensitivity: 0.72; specificity: 0.82; PPV:
0.66; NPV: 0.5) (Bao et al., 2018), 34 ppb (AUC: 0.62; PPV: 0.88;
NPV: 0.62) (Schleich et al., 2012), and 25 ppb (AUC: 0.65; PPV:
0.83; NPV: 0.49) (Bougard et al., 2020), and others (Song et al.,
2017a; Chen et al., 2019). These discrepancies might be explained,
at least partly, by population study differences, including
ethnicity (all Caucasian population vs. all Chinese population)
(Bao et al., 2018), mean age (24 years vs. 43 (Bao et al., 2018) or 41
(Schleich et al., 2012) or 51 (Bougard et al., 2020) years), smoking
habit (nonsmokers vs. 6–19% (Bao et al., 2018) or 34% (Schleich
et al., 2012) current smokers), atopy (35 vs. 93% (Schleich et al.,
2012), not reported in reference 6), symptoms (suspected CVA
vs. suspected asthma with negative bronchodilator reversibility
test (Schleich et al., 2012), and inhaled corticosteroid (ICS)
treatment (Bougard et al., 2020). Atopy seems to paly a robust
role as in a recent paper the diagnostic accuracy of FENO for
predicting CVA in chronic cough in patients with atopy was
clearly higher than in patients without (Chen et al., 2019). Based
on our data, FENO might have a greater predictive value in
distinguishing subjects with or without BHR in young adults
with undifferentiated cough and normal lung function. In this
population, the high BHR predictive accuracy of FENO
measurement (AUC: 0.98; PPV: 0.95; NPP: 0.93; PLR: 21.56;
NLR: 0.08) suggest that BPT should be limited to individuals
with FENO > 32.7 ppb. In this perspective FENO could be used
as a rule-in test for CVA as previously suggested (Song et al.,
2017a).
Measurement of percentage of eosinophil cell counts in
induced sputum as a candidate for predicting BHR is novel. In
the present study, at a cutoff value of 3.8%, this method showed
higher accuracy and BHR predicting capacity (AUC: 0.98; PPV:
0.94; NPV: 0.95) than peripheral blood eosinophil cell counts at a
cutoff value of 3.5% (AUC: 0.76; PPV: 58.9; NPV: 85.1) (Bao et al.,
2018). Apart from variations in study populations, this
inconsistency might derive from methodological differences, as
measurement of eosinophil cell counts in induced sputum is a
direct and likely more accurate measure of airway inflammation
than peripheral blood eosinophils. Along with FENO, sEOS%
showed the highest discriminative capacity to identify BHR POS
individuals under our experimental conditions. However,
measurement of sEOS% is not available in all centers as it
requires trained and experienced staff for sputum induction,
processing and analysis.
Classification above a threshold value of 70% is considered
significant (Bijlsma et al., 2006). In the present study, FEF25–75%
measures showed significant discriminative capabilities as
reflected by AUCs >0.91 with PPV >0.85 and NPV >0.89 at
OCV. FEF25–75% has been found to correlate with functional
imaging assessment of small airway function (Jain et al., 2005).
Small airways disease plays a relevant role in asthma
pathophysiology (Van Der Wiel et al., 2013; van der Wiel
et al., 2014). Airway wall thickening induced by inflammation,
airway narrowing, and enhanced airway muscular tone
contribute to small airway dysfunctions and poorly controlled
asthma (van der Palen et al., 2013). Measurement of FEF25–75%
to detect small airway dysfunction in asthmatic subjects
with normal FEV1 values could be a useful diagnostic tool
(Malerba et al., 2016). Our findings, showing that the
FEF25–75% % predicted values in BHR POS individuals are
lower than those observed in BHR NEG individuals, confirm
the presence of small airway disease in subjects with FVC,
FEV1, and FEV1/FVC values within normal limits. Compared
with FENO at cutoff of 32.7 ppb (AUC: 0.98; sensitivity: 0.93),
FEF25–75% % predicted value showed a lower discriminative
capacity at a cutoff of 80% (AUC: 0.93), but a similar
sensitivity (0.90) using 80% as cutoff value. If inflammatory
measures such as FENO and sEOS% are not available, a
FEF25–75% > 80% predicted value could help rule out CVA
diagnosis in young adults with cough and aid clinicians in
diagnosing BHR positive subjects referring to BPT only
subjects with FEF25–75% < 80% predicted values.
Strengths of our study are represented by assessment and
comparison of both small airway function and inflammatory
potential surrogate markers of BHR, including measurement of
eosinophil counts in induced sputum, and inclusion of a large
cohort of young adults with suspected CVA and normal lung
function as reflected by FEV1 values.
Inclusion of a relatively homogeneous study population
consisting of non-smoker, steroid-naïve, individuals with a
median age of 24 years represents a strength, but, at the same
time, a study limitation as it precludes the assessment of
the impact of confounding factors, including age, ethnicity,
smoking habit, comorbidities, and ICS treatment on study
outcomes. These findings cannot be generalized. FENO
concentration reliably reflects central airway inflammation, but
is not generally considered to reflect peripheral airway
inflammation for which estimating alveolar NO concentration
(CANO) by measurement of FENO at different flow rates
could be more useful (Lehtimäki et al., 2020). Other study
limitations include the lack of internal validation of results
with training and testing datasets and external validation,
the higher prevalence of atopy in BHR POS than in BHR
NEG subjects (68 vs. 6%, respectively), which may have
influenced the outcomes of FENO and sEOS% diagnostic
performance, the lack of assessment of air pollution exposure
potential impact and objective measures of smoking status,
and the absence of post-bronchodilator data. However, the
latter is not usually required in individuals with FEV1 >80%
predicted value. As our study was conducted in young
adults, results and their interpretation should be limited to
this age group. Further research is warranted to determine
if these results can be generalized to older individuals with
asthma.
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Finally, assessment of small airway function was limited to
FEF25–75%. However, other functional measure, including
nitrogen washout and plethysmography, are not routinely used
in clinical practice.
In conclusion, our study shows elevated capacities of
noninvasive/semi-invasive methods, particularly FENO and
sEOS%, in predicting BHR in young adults with suspected
CVA and normal lung function, and points out the
importance of the target population choice in determining
their diagnostic performances. External validation of these
research outcomes in independent cohorts is required before
translating this approach into clinical decision-making.
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